Zentalis Pharmaceuticals, Inc. (ZNTL) – What Are Brokerages Saying About This Stock?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $7.50.

A number of analysts have weighed in on ZNTL shares. William Blair assumed coverage on shares of Zentalis Pharmaceuticals in a report on Wednesday, September 16th. They set an “outperform” rating on the stock. Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price target for the company. Wells Fargo & Company assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 30th. They set an “equal weight” rating and a $5.00 price objective for the company. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an “outperform” rating and a $8.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Friday, October 2nd.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters purchased 4,335,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the acquisition, the insider owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Spark Investment Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth about $61,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $126,000. Stonepine Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $783,678. Seven Fleet Capital Management LP raised its holdings in shares of Zentalis Pharmaceuticals by 188.7% during the second quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock valued at $1,451,000 after buying an additional 207,600 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $5,406,000.

Zentalis Pharmaceuticals Trading Up 5.2%

Shares of ZNTL opened at $2.64 on Monday. Zentalis Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $6.95. The firm has a market cap of $189.21 million, a price-to-earnings ratio of -1.35 and a beta of 1.93. The stock has a 50 day moving average of $3.54 and a 200-day moving average of $3.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.11 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.